Clinical Trials Logo

Major Depressive Disorder clinical trials

View clinical trials related to Major Depressive Disorder.

Filter by:

NCT ID: NCT05385783 Completed - Clinical trials for Major Depressive Disorder

A Study of a Psilocybin Analog (CYB003) in Healthy Participants With and Without Major Depressive Disorder

Start date: August 2, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine the safety and tolerability of ascending oral doses of CYB003 in healthy participants with and without major depressive disorder (MDD).

NCT ID: NCT05384041 Completed - Clinical trials for Major Depressive Disorder

Cranial Electrotherapy Stimulation for the Treatment of Major Depressive Disorder in Adults

CES-MDD
Start date: April 28, 2022
Phase: N/A
Study type: Interventional

This study is designed to evaluate the safety and efficacy of the Fisher Wallace Stimulator FW-200 to deliver Cranial Electrotherapy Stimulation (CES) for the treatment of moderate to severe Major Depressive Disorder (MDD) in adults.

NCT ID: NCT05376150 Completed - Clinical trials for Major Depressive Disorder

A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive Disorder

X-NOVA
Start date: May 19, 2022
Phase: Phase 2
Study type: Interventional

This is a multicenter, Phase 2, double-blind, randomized, parallel-arm, placebo-controlled clinical trial to evaluate the efficacy, safety, and tolerability of XEN1101 in subjects with Major Depressive Disorder.

NCT ID: NCT05355285 Completed - Clinical trials for Major Depressive Disorder

Type 1 Diabetes and Depression: Role of Brain Glutamate

Start date: January 2011
Phase: N/A
Study type: Interventional

The goal of this study is to examine the effect of chronic and acute hyperglycemia in type 1 diabetes mellitus (T1DM) on brain glutamate levels using magnetic resonance spectroscopy (MRS), and associations of brain glutamate with symptoms of depression.

NCT ID: NCT05347199 Completed - Clinical trials for Major Depressive Disorder

Effects of a Single Dose of Amisulpride on Functional Brain Changes

Start date: May 17, 2022
Phase: Phase 1
Study type: Interventional

This study is designed to investigate effects of a single dose of amisulpride on functional brain changes during reward- and motivation-related processing and at rest in healthy volunteers (HV) and in patients with Major Depressive Disorder (MDD).

NCT ID: NCT05271357 Completed - Clinical trials for Major Depressive Disorder

Transcranial Magnetic Stimulation for Depression in Autism Spectrum Conditions

RESTORE
Start date: November 24, 2021
Phase: N/A
Study type: Interventional

In this research study the investigators aim to learn more about the therapeutic effects of a newer form of non-invasive transcranial magnetic stimulation (TMS), called theta burst simulation (TBS), on refractory depression in Autism Spectrum Conditions.

NCT ID: NCT05271084 Completed - Clinical trials for Major Depressive Disorder

Pentoxifylline as an Adjunct to Citalopram in Adult Patients With Major Depressive Disorder

Start date: November 10, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The aim of this study is to test if combining the antidepressant Citalopram with Pentoxifylline (PTX), a medicine with anti-inflammatory and phosphodiesterase inhibitory properties, enhanced antidepressant efficacy in adult patients with major depressive disorder (MDD) when compared to Citalopram alone.

NCT ID: NCT05260086 Completed - Clinical trials for Major Depressive Disorder

Pre-mapping Networks for Brain Stimulation 2

PreNeSt2
Start date: April 15, 2019
Phase: N/A
Study type: Interventional

The investigators compare the primary and secondary outcome measures using accelerated intermittent theta burst stimulation (aiTBS, 20 sessions active and 20 sessions sham in a counterbalanced crossover design) to treat depressive symptoms with 2 parallel arms of intervention: personalized (stimulation position based on participants' brain networks) vs conventional (stimulation in F3 position of the 10-20 EEG cap) aiTBS.

NCT ID: NCT05203341 Completed - Clinical trials for Major Depressive Disorder

Study to Assess the Efficacy and Safety of NBI-1065845 in Adults With Major Depressive Disorder (MDD)

SAVITRI
Start date: February 21, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy of NBI-1065845 compared with placebo in participants with MDD on improving symptoms of depression.

NCT ID: NCT05202119 Completed - Clinical trials for Major Depressive Disorder

Empower: tDCS for Major Depressive Disorder at Home

Start date: May 1, 2022
Phase: N/A
Study type: Interventional

A two-center trial to investigate whether or not active stimulation with the Flow FL-100 tDCS device is superior to sham stimulation for the treatment of major depressive disorder when used at home. Participants perform up to 36 tDCS sessions by themselves without supervision during a blinded 10-week phase, and then 30 more sessions during an unblinded open-label phase.